Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gynaecological cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Gynaecological cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-000988-25 Sponsor Protocol Number: version4 Start Date*: 2012-04-27
    Sponsor Name:Gateshead Health NHS Trust Research & Development
    Full Title: To determine the feasibility of using Microbubble technology to detect sentinel nodes in vulvar cancer.
    Medical condition: Early stage vulvar cancer with no clinial or radiological evidence of lymph node metastases
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003779-36 Sponsor Protocol Number: ICR-CTSU/2018/10066 Start Date*: 2019-10-11
    Sponsor Name:The Institute of Cancer Research
    Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss
    Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073268 Ovarian clear cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009252 Clear cell endometrial carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073269 Ovarian endometrioid carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008224 Cervical adenocarcinoma LLT
    21.1 100000004872 10062718 Endocervical squamous metaplasia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052204 Ovarian carcinosarcoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003192-11 Sponsor Protocol Number: ANZGOG0903 Start Date*: 2012-09-07
    Sponsor Name:University of Sydney [...]
    1. University of Sydney
    2. University of Sydney
    Full Title: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Women with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) potentially hormone responsive recurrent or metastatic gynaecological cancer including selected patients with epitheli...
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000501-52 Sponsor Protocol Number: PARAGON2011 Start Date*: 2011-12-07
    Sponsor Name:Greater Glasgow and Clyde [...]
    1. Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms
    Medical condition: Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups: A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fa...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026310 Malignant neoplasm of ovary LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014760 Endometrial neoplasm malignant LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002918-19 Sponsor Protocol Number: VEG110190 Start Date*: 2007-09-06
    Sponsor Name:GlaxoSmithkline Research & Development Limited
    Full Title: A Phase II, Open-Label, Multicenter Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Previously Untreated, Advanced Gynaecological Tumors
    Medical condition: previously untreated, advanced gynaecological tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    9.1 10014743 Endometrial carcinoma LLT
    9.1 10046821 Uterine sarcoma NOS LLT
    9.1 10016180 Fallopian tube cancer LLT
    9.1 10052171 Peritoneal carcinoma LLT
    9.1 10008229 Cervical cancer LLT
    9.1 10051963 Vulvar carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006069-34 Sponsor Protocol Number: 1564 Start Date*: Information not available in EudraCT
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Clinical efficacy and cell mobilization activity of pegfilgrastim in patients with gynaecological malignancies in therapy with topotecan.
    Medical condition: ovarian cancer, cervical cancer, endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038594 Reproductive neoplasms female malignant and unspecified HLGT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017282-35 Sponsor Protocol Number: 113617 Start Date*: 2010-07-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects
    Medical condition: GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of pre-malignant cervical lesions and cervical cancer causally related to Hum...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022482-95 Sponsor Protocol Number: BGOG-ov-5 Start Date*: 2012-02-07
    Sponsor Name:Belgian Gynaecological Oncolgy Group
    Full Title: BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.
    Medical condition: recurrence of ovarian, fallopian tube or peritoneal carcinoma, cervical carcinoma or endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008231 Cervical cancer recurrent LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023081-52 Sponsor Protocol Number: ENGOT-EN2-DGCG Start Date*: 2011-01-25
    Sponsor Name:Danish Gynaecological Cancer Group (DGCG)
    Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014739 Endometrial cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004168-36 Sponsor Protocol Number: UCL/17/0672 Start Date*: 2018-10-16
    Sponsor Name:University College London
    Full Title: A phase II study of pembrolizumab in patients with advanced gynaecological clear cell cancer
    Medical condition: Advanced Gynaecological Clear Cell Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009252 Clear cell endometrial carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047741 Vulval cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004076-19 Sponsor Protocol Number: ENGOT-cx1/BGOG-cx1 Start Date*: 2013-10-28
    Sponsor Name:UZ Leuven / Belgian Gynaecological Oncology Group
    Full Title: ENGOT-cx1/BGOG-cx1: "Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in adv...
    Medical condition: Advanced or recurrent cervical carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004738-39 Sponsor Protocol Number: ENGOT-OV56/NSGO-CTU-DOVACC Start Date*: 2021-08-20
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit
    Full Title: ENGOT-OV56-NSGO-CTU-DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) GR (Prematurely Ended) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003756-20 Sponsor Protocol Number: ENGOT-Cx7-NSGO/MaRuC Start Date*: 2019-10-08
    Sponsor Name:Nordic Society of Gynaecological Oncology-Clinical Trial Unit
    Full Title: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer
    Medical condition: Cancer of uterine cervix
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004864 10008233 Cervical cancer stage I LLT
    21.1 100000004864 10008234 Cervical cancer stage II LLT
    21.1 100000004864 10008235 Cervical cancer stage III LLT
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004071-34 Sponsor Protocol Number: PRG-Opioid-06-/03 Start Date*: 2009-01-14
    Sponsor Name:Queen Mary, University of London (QMUL)
    Full Title: A single centre, parallel group, pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling.
    Medical condition: This study is not looking at any disease process
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017946-30 Sponsor Protocol Number: 20060517 Start Date*: 2011-01-19
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Prim...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) SK (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed) DK (Completed) DE (Completed) PL (Completed) GR (Completed) LV (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005610-37 Sponsor Protocol Number: PROTEC1 Start Date*: 2015-05-07
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: PROgesterone Therapy for Endometrial Cancer prevention in obese women (PROTEC)
    Medical condition: Proliferation of the endometrium.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000277-72 Sponsor Protocol Number: ARRAY-162-311 Start Date*: 2013-09-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or...
    Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001112-53 Sponsor Protocol Number: 20101129 Start Date*: 2012-01-09
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, P...
    Medical condition: FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed) ES (Completed) BE (Completed) NL (Completed) AT (Completed) DK (Prematurely Ended) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001576-11 Sponsor Protocol Number: 4010-03-001 Start Date*: 2019-09-10
    Sponsor Name:TESARO, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced...
    Medical condition: Recurrent or primary advanced (Stage III or IV) endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005990-29 Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO Start Date*: 2021-12-14
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
    Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 00:23:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA